Revenue collapsed 71% with just NZ$5.5m generated in H2 as book runs off

What changed

Interest and fee income fell to NZ$39.2m from NZ$135.4m (-71.1%). The reported loss narrowed to NZ$382.3m from NZ$427.5m, a 10.6% improvement on both a PBT and NPAT basis (tax was nil in both years, so the two measures are identical). Operating cash flow was still positive at NZ$127.1m but down 30.2% on NZ$182.0m in FY21.

The balance sheet contracted sharply. Total assets fell 54.4% to NZ$1.2b, gross borrowings reduced 58.4% to NZ$985.5m, but cash collapsed 92.5% to NZ$148.3m from NZ$2b. As a result net debt rose to NZ$837.2m from NZ$381.9m despite the headline debt reduction. Equity was down 12.1% to NZ$231.0m. No dividend has been declared.

What matters

• H2 was effectively dormant. HY22 revenue was NZ$33.8m versus FY22 revenue of NZ$39.2m, implying just NZ$5.5m of income in the second half. The H2 NPAT was also worse than H1 (NZ$-166.6m vs NZ$-215.7m in H1, so H2 contributed roughly 44% of the full-year loss on almost no revenue), pointing to the bulk of the operating base having been wound down rather than trading through.
• Liquidity and leverage deterioration. The NZ$1.84bn cash outflow used to repay borrowings reduced gross debt but also stripped out the offsetting cash asset, pushing net debt materially higher. Without a disclosed EBITDA or cash-generating run rate, the remaining NZ$985.5m of borrowings is not visibly serviced by current revenue.
• Shell / RTO context. The interim filing language references a planned reverse takeover and capitalisation to fund working capital, which is consistent with the run-off pattern in the P&L and balance sheet. The published numbers are therefore describing a legacy book in wind-down, not a going concern trading position.

Expectations

No forward-work, forward guidance, or stated revenue/earnings targets were provided in the extracts, so the result cannot be benchmarked against management ambition. The only shape signal available is the interim comparison, which shows the year was heavily first-half weighted (H1 accounted for 86.1% of full-year revenue). On that basis the release does not support any view of a stabilising revenue base; it supports the opposite, that the income-producing assets were substantially gone by period-end.

Quality of result

The 10.6% narrowing of the loss is not a sign of operational improvement. Revenue fell 71.1% while operating cash flow, though still positive at NZ$127.1m, is clearly a product of collecting down the loan/receivable book rather than ongoing trading — H2 operating cash flow was implied negative at roughly NZ$-204m against NZ$331m in H1. Capex was nil (FY21: NZ$1.0m), so headline pre-lease free cash flow of NZ$127.1m reflects balance-sheet liquidation, not earnings. ROE remains deeply negative at -165.6% and directionally worse than the prior year. Overall, very little of this result looks durable; it is balance-sheet-driven.

Unresolved

• What exactly drove the NZ$382.3m reported loss — impairments, fair-value adjustments on the borrowing book, or operating losses? No non-recurring items are disclosed in the extracts.
• What is the composition and recoverability of the remaining NZ$1.2b of assets against NZ$985.5m of borrowings, and are any covenants or maturity concentrations attached?
• On what terms and timeline is the flagged reverse takeover / capitalisation expected to proceed, and what does it imply for existing holders' equity (currently NZ$231.0m)?
• Is there any residual revenue-generating activity at all after the NZ$5.5m H2 run rate, or is the entity effectively a cash/debt shell?

This briefing cannot assess solvency, the nature of the underlying loss drivers, or the structure and dilution of the prospective reverse takeover, because none of those items are disclosed in the supplied extracts.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.